Trial Profile

A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vadadustat (Primary) ; Darbepoetin alfa; Epoetin alfa
Indications Anaemia
Focus Pharmacodynamics; Pharmacokinetics
Sponsors Akebia Therapeutics

Most Recent Events

12 Sep 2023 Results assessing Pharmacokinetics, Pharmacodynamics & Safety of Vadadustat in Hemodialysis Patients With Anemia As- sociated With Chronic Kidney Disease presented at the 2023 American College of Clinical Pharmacology Annual Meeting
05 Aug 2020 Status changed from active, no longer recruiting to completed.
15 Jun 2020 Planned End Date changed from 30 Apr 2020 to 1 Jul 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com